• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Inhibikase Therapeutics Inc.

    3/27/25 5:01:43 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IKT alert in real time by email
    S-8 1 d928021ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 27, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    INHIBIKASE THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   26-3407249

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    Stock Option Inducement Awards

    (Full Title of the Plans)

    Mark Iwicki

    Chief Executive Officer

    3350 Riverwood Parkway SE, Suite 1900

    Atlanta, GA 30339

    (Name and Address of Agent For Service)

    (678) 392-3419

    (Telephone Number, Including Area Code, of Agent For Service)

     

     

    Copies to:

    Danielle Lauzon

    Marishka DeToy

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 registers 20,121,377 shares of common stock, par value $0.001 per share (“Common Stock”), of Inhibikase Therapeutics, Inc. (the “Registrant”), issuable under the inducement stock option awards granted on February 14, 2025 and February 21, 2025 (collectively, the “Inducement Awards”). The Inducement Awards were approved by the Registrant’s board of directors, in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4). The Inducement Awards were granted outside of the Registrant’s 2020 Equity Incentive Plan.


    Part I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of the Form S-8 instructions. The documents containing the information specified in Part I will be delivered to the persons to whom the Inducement Awards have been granted as required by Rule 428(b)(1) under the Securities Act.


    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents filed with the Commission:

     

      •  

    Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2025;

     

      •  

    Current Reports on Form 8-K filed with the SEC on January  6, 2025, January  29, 2025, February  18, 2025 (excluding Item 7.01) and February 24, 2025 (excluding Item 7.01); and

     

      •  

    The description of the Registrant’s Common Stock contained in the Registration Statement on Form 8-A filed with the SEC on October 29, 2020, together with any amendment thereto filed with the SEC for the purpose of updating such description.

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law empowers a corporation to indemnify its directors and officers and to purchase insurance with respect to liability arising out of their capacity or status as directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in our best interests, and, with respect to any criminal action, had no reasonable cause to believe the person’s actions were unlawful. The Delaware General Corporation Law further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation’s bylaws, any agreement, a vote of stockholders or otherwise. The amended and restated certificate of incorporation of the Registrant provides for the indemnification of the Registrant’s directors and officers to the fullest extent permitted under the Delaware General Corporation Law. In addition, the amended and restated bylaws of the Registrant require the Registrant to fully indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director or officer of the Registrant,


    or is or was a director or officer of the Registrant serving at the Registrant’s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law.

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) for payments of unlawful dividends or unlawful stock repurchases or redemptions; or (iv) for any transaction from which the director derived an improper personal benefit. The Registrant’s amended and restated certificate of incorporation provides that the Registrant’s directors shall not be personally liable to it or its stockholders for monetary damages for breach of fiduciary duty as a director and that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the Registrant’s directors shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.

    As permitted by the Delaware General Corporation Law, the Registrant has entered into separate indemnification agreements with each of the Registrant’s directors and certain of the Registrant’s officers which require the Registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors, officers or certain other employees.

    The Registrant has obtained and maintains insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not the Registrant would have the power to indemnify such person against such liability under the provisions of the Delaware General Corporation Law.

    These indemnification provisions and the indemnification agreements the Registrant intends to enter into between the Registrant and the Registrant’s officers and directors may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act of 1933, as amended.

    Item 7. Exemption from Registration Claimed.

    Not applicable.


    Item 8. Exhibits.

    EXHIBIT INDEX

     

    Exhibit
    No.
      

    Description

     4.1    Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39676) filed on December 29, 2020).
     4.2    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39676) filed on January 6, 2025).
     4.3    Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-39676) filed on December 29, 2020).
     4.4    Form of Certificate of Common Stock (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-240036) filed on July 23, 2020).
     5.1*    Opinion of Goodwin Procter LLP.
    23.1*    Consent of CohnReznick LLP, Independent Registered Public Accounting Firm.
    23.2*    Consent of Goodwin Procter LLP (included as part of Exhibit 5.1).
    24.1*    Power of Attorney (included on signature page).
    99.1    Form of Non-Qualified Stock Option Agreement (Non-Plan Inducement Grant) (incorporated herein by reference to Exhibit 10.30 to the Registrant’s Annual Report on Form 10-K (File No. 001-39676) filed on March 27, 2025).
    107*    Filing Fee Table

     

    *

    Filed herewith.


    Item 9. Undertakings.

    (a) The Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act.

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement.

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Atlanta, State of Georgia, on March 27, 2025.

     

    INHIBIKASE THERAPEUTICS, INC.
    By:  

    /s/ Mark Iwicki

    Name:   Mark Iwicki
    Title:   Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL MEN BY THESE PRESENTS, that each officer and director of Inhibikase Therapeutics, Inc. whose signature appears below constitutes and appoints Mark Iwicki and Garth Lees-Rolfe and each of them, his true and lawful attorney-in-fact and agent, with full power of substitution and revocation, for him and in his name, place and stead, in any and all capacities, to execute any or all amendments including any post-effective amendments and supplements to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.


    Signature

      

    Title

     

    Date

    /s/ Mark Iwicki

    Mark Iwicki

      

    Chief Executive Officer and Director

    (Principal Executive Officer)

      March 27, 2025

    /s/ Garth Lees-Rolfe

    Garth Lees-Rolfe, CPA

      

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

      March 27, 2025

    /s/ Amit Munshi

    Amit Munshi

       Chairperson   March 27, 2025

    /s/ Dennis Berman

    Dennis Berman

       Director   March 27, 2025

    /s/ David Canner

    David Canner

       Director   March 27, 2025

    /s/ Roy Freeman, M.D.

    Roy Freeman, M.D.

       Director   March 27, 2025

    /s/ Arvind Kush

    Arvind Kush

       Director   March 27, 2025

    /s/ Roberto Bellini

    Roberto Bellini

       Director   March 27, 2025

    /s/ Vincent Aurentz

    Vincent Aurentz

       Director   March 27, 2025
    Get the next $IKT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IKT

    DatePrice TargetRatingAnalyst
    2/12/2025Buy → Neutral
    H.C. Wainwright
    7/15/2021$12.00Buy
    JonesTrading
    More analyst ratings

    $IKT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

      BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025. "David has extensive experience in financial strategy and corporate governance, as well as an established reputation within the life sciences capital markets sector, and we are thrilled to welcome him as our new Chief Financial Officer," said Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics. "We look for

      4/14/25 8:00:00 AM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

      BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today reported financial results for the year ended December 31, 2024 and highlighted recent developments. "The financing concluded in October positioned us to focus our clinical development efforts on advancing IkT-001 toward a late-stage clinical trial in PAH," said Mark Iwicki, Chief Executive Officer of Inhibikase. "To drive the Company toward its next phase of growth, we subsequently added depth to our management team with the

      3/27/25 4:01:00 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibikase Announces Expansion of Senior Leadership Team

      --- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension ("PAH") to its senior leadership team. Chris Cabell, M.D., former Chief Medical Officer of Arena Pharmaceuticals and Chief Executive Officer of CorHepta Pharmaceuticals, Inc. ("CorHepta") has been appointed as President and Head of Research & D

      2/24/25 8:00:00 AM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKT
    Financials

    Live finance-specific insights

    See more
    • Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

      BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 15, 2024, to provide a corporate update and review the financial results. The

      8/7/24 8:00:08 AM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

      BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the first quarter ended March 31, 2024 and highlighted recent developments. "2024 is shaping up to be a year of clinical and regulatory execution as we advance our core programs towards important inflection points," said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. "The Phase 2 201 t

      5/15/24 8:00:00 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

      BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent developments. "2023 was a year of clinical execution across our pipeline, culminating in the recent pre-NDA meeting with the FDA for IkT-001Pro and robust enrollment of untreated Parkinson's patients in our 201 Trial evaluating Risvod

      3/27/24 4:15:20 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Inhibikase Therapeutics Inc.

      SC 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)

      11/14/24 3:31:08 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Inhibikase Therapeutics Inc.

      SC 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)

      10/28/24 5:26:55 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Inhibikase Therapeutics Inc.

      SC 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)

      10/28/24 4:00:29 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Inhibikase Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Inhibikase Therapeutics from Buy to Neutral

      2/12/25 7:05:10 AM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JonesTrading initiated coverage on Inhibikase Therapeutics with a new price target

      JonesTrading initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $12.00

      7/15/21 9:29:48 AM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Mcintyre David

      4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

      4/16/25 4:06:03 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Mcintyre David claimed ownership of 10,285 shares (SEC Form 3)

      3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

      4/16/25 4:05:04 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President & Head of R&D Cabell Christopher

      4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

      2/25/25 4:10:05 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bellini Roberto bought $2,000,200 worth of shares (1,460,000 units at $1.37) (SEC Form 4)

      4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

      10/23/24 7:53:27 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kush Arvind bought $198,650 worth of shares (145,000 units at $1.37) (SEC Form 4)

      4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

      10/23/24 7:49:49 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Munshi Amit bought $500,050 worth of shares (365,000 units at $1.37) (SEC Form 4)

      4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

      10/23/24 7:43:35 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKT
    Leadership Updates

    Live Leadership Updates

    See more
    • Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

      BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025. "David has extensive experience in financial strategy and corporate governance, as well as an established reputation within the life sciences capital markets sector, and we are thrilled to welcome him as our new Chief Financial Officer," said Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics. "We look for

      4/14/25 8:00:00 AM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibikase Announces Expansion of Senior Leadership Team

      --- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension ("PAH") to its senior leadership team. Chris Cabell, M.D., former Chief Medical Officer of Arena Pharmaceuticals and Chief Executive Officer of CorHepta Pharmaceuticals, Inc. ("CorHepta") has been appointed as President and Head of Research & D

      2/24/25 8:00:00 AM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

      -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced the appointment of Mark Iwicki as the Company's Chief Executive Officer, replacing Dr. Milton H. Werner, founder of Inhibikase, effective February 14, 2025. Additionally, effective February 14, 2025, Amit Munshi, a member of the Board of Directors of the Company (the "Board") and veteran biopharmaceutical industry executive with deep experience in PAH, has been appoin

      2/18/25 8:00:00 AM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKT
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Inhibikase Therapeutics Inc.

      PRE 14A - Inhibikase Therapeutics, Inc. (0001750149) (Filer)

      5/2/25 4:05:04 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 10-K/A filed by Inhibikase Therapeutics Inc.

      10-K/A - Inhibikase Therapeutics, Inc. (0001750149) (Filer)

      4/25/25 4:05:10 PM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Inhibikase Therapeutics Inc.

      8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)

      4/14/25 8:16:40 AM ET
      $IKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care